The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering
Inc () has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Inc (), to use its Flow Electroporation Technology (FET) platform.
The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering.
Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.
Doug Doerfler, president and chief executive of , said Kite would be utilising the firm’s platform to enable gene-editing technologies for the research and development of new therapeutics.
The deal follows a commercial license agreement signed last week between and gene-based medicine maker CRISPR Therapeutics in a move to advance the development of anti-cancer treatments.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE